| Previous close | 5.28 |
| Open | 5.09 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 135.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.84 - 5.75 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Barrons.comHims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.
ZacksTop Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
ZacksPlay These New ETFs to Tap Lucrative Weight Loss Drug Market
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
